Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 207 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Alexion Pharmaceuticals, Inc. Clear all
Completed Phase 2 Interventional Results available

Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)

NCT00935883
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Eculizumab, Saline
Drug
Lead sponsor
Philip J. Rosenfeld, MD, PhD
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 17, 2026, 4:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects

NCT01883544
View directory record Official record
Conditions
Healthy Subjects
Interventions
ALXN1007
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
25 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 17, 2026, 4:17 AM EDT
Recruiting No phase listed Observational

Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

NCT05966467
View directory record Official record
Conditions
Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 4:17 AM EDT
Completed Phase 2 Interventional Results available

Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840

NCT04422431
View directory record Official record
Conditions
Wilson Disease
Interventions
Bis-Choline Tetrathiomolybdate
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Sacramento, California • Ann Arbor, Michigan • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 17, 2026, 4:17 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)

NCT03075878
View directory record Official record
Conditions
Warm Autoimmune Hemolytic Anemia
Interventions
ALXN1830
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 17, 2026, 4:17 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid

NCT02226146
View directory record Official record
Conditions
Pemphigoid, Bullous
Interventions
Bertilimumab
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Iowa City, Iowa • Buffalo, New York • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 17, 2026, 4:17 AM EDT
Completed Phase 2 Interventional Results available

Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency

NCT01488097
View directory record Official record
Conditions
Cholesterol Ester Storage Disease (CESD), Lysosomal Acid Lipase Deficiency, LAL-Deficiency
Interventions
sebelipase alfa
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
5
States / cities
Eureka, California • Sacramento, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Oct 17, 2026, 4:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Potential Drug Interaction Between ALXN2040 and Rosuvastatin

NCT05708573
View directory record Official record
Conditions
Healthy Participants
Interventions
Rosuvastatin, ALXN2040
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 17, 2026, 4:17 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia

NCT04369469
View directory record Official record
Conditions
COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome, Pneumonia, Viral
Interventions
Ravulizumab, BSC
Biological · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
24
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 17, 2026, 4:17 AM EDT
Completed Phase 1 Interventional Results available

Study of ALXN1850 in Participants With Hypophosphatasia (HPP)

NCT04980248
View directory record Official record
Conditions
Hypophosphatasia
Interventions
ALXN1850
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Las Vegas, Nevada • Columbus, Ohio • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 17, 2026, 4:17 AM EDT
Withdrawn Phase 2 Interventional

Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis

NCT04982289
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
ALXN1830, Placebo
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 17, 2026, 4:17 AM EDT
Terminated Phase 2 Interventional

Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.

NCT00040157
View directory record Official record
Conditions
HIV Infections
Interventions
ACH126-443 (Beta-L-Fd4C)
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Oct 17, 2026, 4:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of Food and Age on Danicopan

NCT04551599
View directory record Official record
Conditions
Healthy
Interventions
Danicopan
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 17, 2026, 4:17 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis

NCT03920293
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Ravulizumab, Placebo
Biological · Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
49
States / cities
Phoenix, Arizona • Irvine, California • Loma Linda, California + 43 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 17, 2026, 4:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa

NCT03083704
View directory record Official record
Conditions
Bleeding
Interventions
Andexanet alfa (Gen 1 Process 2), Apixaban 5 MG, Rivaroxaban 20 MG, Enoxaparin sodium, Edoxaban 60 MG, Andexanet alfa (Gen 2), Andexanet alfa (Gen 1 Process 3), Apixaban 10 MG, Rivaroxaban 10 MG
Biological · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 17, 2026, 4:17 AM EDT
Withdrawn Phase 2 Interventional

Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab

NCT01275287
View directory record Official record
Conditions
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions
Standard of care treatment, eculizumab
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 17, 2026, 4:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency

NCT01307098
View directory record Official record
Conditions
Cholesterol Ester Storage Disease(CESD), Lysosomal Acid Lipase Deficiency, LAL-Deficiency
Interventions
Sebelipase alfa 0.35 mg/kg, Sebelipase alfa 1 mg/kg, Sebelipase alfa 3 mg/kg
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Stanford, California • New York, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 17, 2026, 4:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)

NCT03551730
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PRT064445/Enoxaparin, Placebo/Enoxaparin, Placebo
Combination Product · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 17, 2026, 4:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote

NCT03218241
View directory record Official record
Conditions
Healthy
Interventions
PRT064445, Placebo
Biological · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 17, 2026, 4:17 AM EDT
Completed No phase listed Observational Results available

Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patients With Juvenile-onset HPP Who Served as Historical Controls in ENB-006-09

NCT02235493
View directory record Official record
Conditions
Hypophosphatasia, Bone Disease
Interventions
Retrospective Case Only
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
5 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 17, 2026, 4:17 AM EDT
Terminated Phase 2 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection

NCT00401947
View directory record Official record
Conditions
HCV Infection
Interventions
ACH-0137171
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 17, 2026, 4:17 AM EDT
Completed No phase listed Observational

An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype

NCT01528917
View directory record Official record
Conditions
Cholesterol Ester Storage Disease(CESD), Lysosomal Acid Lipase Deficiency
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
5 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Stanford, California • Chicago, Illinois • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 17, 2026, 4:17 AM EDT
Completed Phase 2 Interventional Results available

Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS

NCT00844545
View directory record Official record
Conditions
Atypical Hemolytic Uremic Syndrome
Interventions
Eculizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
Atlanta, Georgia • Fort Wayne, Indiana • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Oct 17, 2026, 4:17 AM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism

NCT05778071
View directory record Official record
Conditions
Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions
eneboparatide, Placebo
Combination Product
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
16
States / cities
Torrance, California • Denver, Colorado • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 17, 2026, 4:17 AM EDT